Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

Table 2 HIF targeted agents in cancer therapy

Agents	Model	Regulatory mechanisms	Refs.
17-allyl-amino-geldanamycin	Human glioma cell lines	Geldanamycin decreases cancer cell migration via HIF1A degradation	[169]
PX-478	Esophageal squamous cancer cells	HIF1A inhibitor PX-478 promotes apoptosis and inhibits G2/M transition contributing to tumor cell proliferation	[170]
PX-12	HT-29 colon carcinoma cell line	Thioredoxin-1 inhibitor decreases the tumor vascular permeability by downregulating HIF1A protein levels and VEGF expression	[41]
PT2385	Human ccRCC tumor cells	HIF2A inhibitor PT2385 hinders cancer metastases by dissociating HIF2A complexes	[172]
PT2399	786-O cells Human ccRCC tumor cells	HIF2A small molecule inhibitor PT2399 causes tumor regression	[173]
AFP464	Human cancer cells lines	Aminoflavone inhibits HIF1 and HIF2 transcriptional protein accumulation for anti-cancer activity	[174]
Acriflavine	HEK293 cells Human P493 cells	Acriflavine inhibits the HIF1 dimerization and has inhibitory effects on tumors growth	[175]
Chetomin	HCT116 cells	Epidithiodiketopiperazines could inhibit the HIF1A-p300 binding via zinc ion ejection	[176]

ISSN: 1756-8722